Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ravi Kumar Jalluri is active.

Publication


Featured researches published by Ravi Kumar Jalluri.


Annual Reports in Medicinal Chemistry | 2014

Chapter Ten - H4 Receptor Antagonists and Their Potential Therapeutic Applications

David D. Burns; Niu Shin; Ravi Kumar Jalluri; Wenqing Yao; Peggy Scherle

Abstract The histamine H 4 receptor shows generally restricted expression in immune cells and has been shown to mediate histamine induced-chemotaxis, suggesting that it may play a role in inflammation. This has led to the discovery and characterization of histamine H 4 receptor antagonists from multiple chemical scaffolds. These antagonists have shown efficacy in numerous preclinical models of inflammation, further supporting the critical role of the histamine H 4 receptor in inflammatory diseases, including rheumatoid arthritis, asthma, pruritis and inflammatory pain. The first histamine H 4 receptor antagonists have entered into clinical trials and data are expected soon to establish the importance of targeting this receptor as a novel therapeutic in inflammation. This review focuses on the histamine H 4 receptor antagonists that have been identified to date.


Archive | 2005

Tetracyclic inhibitors of Janus kinases

James D. Rodgers; Darius J. Robinson; Argyrios G. Arvanitis; Thomas Maduskuie; Stacey Shepard; Louis Storace; Haisheng Wang; Maria Rafalski; Ravi Kumar Jalluri; Andrew P. Combs; Matthew L. Crawley


Archive | 2004

Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases

Yun-Long Li; Jincong Zhuo; David M. Burns; Wenqing Yao; Ravi Kumar Jalluri


Archive | 2008

Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors

James D. Rodgers; Stacey Shepard; Thomas Maduskuie; Haisheng Wang; Nikoo Falahatpisheh; Maria Rafalski; Argyrios G. Arvanitis; Louis Storace; Ravi Kumar Jalluri


Archive | 2007

Triazolotriazines as kinase inhibitors

Jincong Zhuo; Colin Zhang; Meizhong Xu; Ding-Quan Qian; Wenqing Yao; Ravi Kumar Jalluri


Clinical Cancer Research | 2018

The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies

Matthew C. Stubbs; Timothy Burn; Richard B. Sparks; Thomas Maduskuie; Sharon Diamond; Mark Rupar; Xiaoming Wen; Alla Volgina; Nina Zolotarjova; Paul Waeltz; Margaret Favata; Ravi Kumar Jalluri; Huiqing Liu; Xuesong Mike Liu; Jun Li; Robert Collins; Nikoo Falahatpisheh; Padmaja Polam; Darlise DiMatteo; Patricia Feldman; Valerie Dostalik; Pramod Thekkat; Christine Gardiner; Xin He; Yanlong Li; Maryanne Covington; Richard Wynn; Bruce Ruggeri; Swamy Yeleswaram; Chu Xue


Archive | 2016

Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma

Artem Shvartsbart; Stacey Shepard; Andrew P. Combs; Lixin Shao; Nikoo Falahatpisheh; Ge Zou; Andrew W. Buesking; Richard B. Sparks; Eddy W. Yue; Ravi Kumar Jalluri


Archive | 2016

Heterocyclic compounds as pi3k-gamma inhibitors

Artem Shvartsbart; Stacey Shepard; Andrew P. Combs; Lixin Shao; Nikoo Falahatpisheh; Ge Zou; Andrew W. Buesking; Richard B. Sparks; Eddy W. Yue; Ravi Kumar Jalluri


Archive | 2007

Utilisation de triazolotriazines en tant qu'inhibiteurs des kinases

Jincong Zhuo; Colin Zhang; Meizhong Xu; Ding-Quan Qian; Wenqing Yao; Ravi Kumar Jalluri


Archive | 2006

Pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] heteroaryl substituted pyrimidines as inhibitors of Janus kinases

James D. Rodgers; Stacey Shepard; Thomas P. Maduskuie; Haisheng Wang; Nikoo Falahatpisheh; Maria Rafalski; Argyrios G. Arvanitis; Louis Storace; Ravi Kumar Jalluri; Jordan S. Fridman; Krishna Vaddi

Collaboration


Dive into the Ravi Kumar Jalluri's collaboration.

Researchain Logo
Decentralizing Knowledge